Cardiogen Research Guide

Overview

Cardiogen is the trade designation for the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), a member of the peptide bioregulator class originally developed through Russian gerontological and molecular biology research programs. Structurally, Cardiogen consists of four amino acid residues — alanine, glutamic acid, aspartic acid, and arginine — joined in a linear sequence, with a molecular formula of approximately C₁₈H₃₁N₇O₉ and a molecular weight of approximately 489.5 g/mol.

Cardiogen belongs to a broader family of short peptide bioregulators, sometimes referred to as “Khavinson peptides” after the research group most closely associated with their development, which also includes related short peptides studied for tissue-specific regulatory activity. Within this class, Cardiogen (AEDR) has been studied specifically in relation to cardiovascular tissue biology, including cardiomyocyte and vascular research models. This guide focuses exclusively on published cardiovascular-tissue-related research findings rather than usage protocols. Available for research at Iron Peak Peptides: Cardiogen.

The bioregulator peptide concept, as developed in this research tradition, is built on the premise that very short peptides — typically two to seven amino acid residues in length — can exert tissue-selective regulatory effects that are distinct from the receptor-mediated signaling mechanisms associated with larger signaling peptides and growth factors. Cardiogen is one of a series of such short peptides studied for organ- or tissue-specific activity, with cardiac and vascular tissue identified as its primary area of research interest, distinguishing it from other bioregulator peptides in the same structural family that have instead been studied in relation to cartilage, skin, or neural tissue.

Mechanism of Action

Short peptide bioregulators such as Cardiogen are proposed to act, at least in part, through direct interaction with nuclear chromatin. Published biophysical and molecular modeling research on this peptide class describes short peptides binding to specific nucleotide sequences within DNA promoter regions and interacting with histone proteins through hydrogen bonding and electrostatic interactions. This DNA- and histone-binding activity has been proposed as a mechanism by which short regulatory peptides influence gene transcription and epigenetic states, including modulation of DNA methylation patterns associated with cellular aging and differentiation (Khavinson et al., 2021).

In the specific context of cardiovascular biology, Cardiogen has been described in organotypic tissue culture research as stimulating cell proliferation activity in explanted myocardial tissue, with a parallel decrease in immunohistochemically detected p53 protein expression, suggesting a proposed role in modulating apoptosis-related signaling within cardiac tissue explants (Chalisova et al., 2009). More recent review-level research has situated the AEDR tetrapeptide within the study of the senescence-associated secretory phenotype (SASP) and “inflammaging” — the low-grade, chronic inflammatory state associated with cellular senescence — describing AEDR alongside other vasoprotective peptides as a candidate regulator of the signaling molecules, including cytokines and anti-proliferative proteins, that characterize senescent cardiovascular tissue cells (Khavinson et al., 2022).

Published Research

Published research on Cardiogen and the broader short-peptide bioregulator class provides converging evidence for a role in cardiovascular tissue regulation, situated within a larger body of work on peptide-mediated gene expression and cellular senescence.

Chalisova and colleagues examined the tetrapeptide Cardiogen alongside 20 individual amino acids in an organotypic tissue culture model, comparing effects on cell proliferation and apoptosis markers in myocardial tissue explants from young (3-month-old) and aged (24-month-old) rats. While only a minority of the tested amino acids stimulated proliferation in tissue from aged animals, Cardiogen was reported to produce a pronounced stimulatory effect on proliferation in myocardial tissue explants from both age groups, accompanied by a reduction in p53 protein expression detected by immunohistochemistry (Chalisova et al., 2009).

Khavinson and colleagues, in a 2022 review of the senescence-associated secretory phenotype and inflammaging in cardiovascular system cells, discussed the AEDR tetrapeptide alongside other vasoprotective polypeptides — including relaxin mimetics, atrial natriuretic peptide, and the KED tripeptide — as candidate regulators of the cytokine and signaling-molecule pool (including IL-6, IL-8, TNFα, and NF-κB-linked pathways) implicated in age-associated cardiovascular pathology, framing continued peptide-based research as a route toward better understanding the molecular drivers of vascular and myocardial aging (Khavinson et al., 2022).

Khavinson and colleagues, in a broader systematic review of peptide regulation of gene expression, described the molecular basis by which short peptides of two to seven amino acid residues interact with nucleosomes, histone proteins, and single- and double-stranded DNA, discussing AEDR/Cardiogen specifically for its association with regulation of cardiovascular system function within this framework (Khavinson et al., 2021).

Earlier foundational work by Anisimov and Khavinson summarized several decades of research into peptide bioregulation of aging, describing a broad experimental and observational research program examining how tissue-specific short peptide bioregulators, administered in various animal models, correlate with markers of biological aging across multiple organ systems, including cardiovascular tissue (Anisimov & Khavinson, 2010).

Taken together, this literature situates Cardiogen within a defined peptide bioregulator research tradition emphasizing epigenetic and transcriptional mechanisms, with cardiovascular-specific findings concentrated on myocardial tissue proliferation markers, apoptosis-related protein expression, and the pool of cytokines and signaling molecules associated with cardiovascular cell senescence.

Chemical Properties & Specifications

• Common name: Cardiogen
• Chemical designation: Ala-Glu-Asp-Arg (AEDR) tetrapeptide
• Peptide class: Short peptide bioregulator (bioregulator peptide family)
• Amino acid sequence: Alanine – Glutamic acid – Aspartic acid – Arginine
• Molecular formula: Approximately C₁₈H₃₁N₇O₉
• Molecular weight: Approximately 489.5 g/mol
• Appearance: White to off-white lyophilized powder
• Storage: Store lyophilized peptide at -20°C, protected from moisture and light. Once reconstituted, solutions should be stored at 2-8°C and used within the timeframe established by the supplying laboratory; repeated freeze-thaw cycling should be avoided to preserve peptide integrity.

Research Applications

Cardiogen is used in laboratory research primarily within the fields of cardiovascular tissue biology, molecular gerontology, and cellular senescence. Specific research applications include organotypic and explant tissue culture studies examining cardiomyocyte proliferation markers and apoptosis-related protein expression, as well as investigations into the pool of cytokines, matrix metalloproteinases, and other signaling molecules implicated in the senescence-associated secretory phenotype of cardiovascular system cells.

Researchers in the bioregulator peptide field also study Cardiogen as part of comparative work examining tissue-selective activity across the broader family of short regulatory peptides, several of which have been associated in the literature with different organ systems, such as skin, cartilage, and vasculature. Additional research contexts include biogerontology studies exploring the relationship between short peptide bioregulators and markers of cellular and tissue aging, and structural biology research using molecular modeling and docking approaches to characterize how short peptides such as Cardiogen may interact with DNA and histone targets at the molecular level.

Given the persistent research interest in the molecular biology of cardiovascular aging and inflammaging, Cardiogen and related cardioprotective research peptides continue to be examined as tool compounds for probing the signaling pathways that govern cardiomyocyte proliferation, vascular cell senescence, and the balance between pro-inflammatory and reparative processes in cardiovascular tissue. Researchers frequently position such short peptide bioregulators alongside other classes of cardiovascular-directed research molecules, including natriuretic peptides and relaxin mimetics, when designing comparative in vitro or ex vivo cardiac and vascular models.

References

1. Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IuA, Zhekalov AN. (2009). The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Advances in Gerontology.
2. Khavinson V, Linkova N, Dyatlova A, et al. (2022). Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells.
3. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules.
4. Anisimov VN, Khavinson VK. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology.